Document Detail


Prevention of serious cardiac events by low-dose aspirin in patients with silent myocardial ischaemia. The Research Group on Instability in Coronary Artery Disease in Southeast Sweden.
MedLine Citation:
PMID:  1354274     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
On exercise testing after an episode of unstable coronary artery disease (CAD; unstable angina or non-Q-wave myocardial infarction), a proportion of patients show ST-segment depression, indicating myocardial ischaemia, but do not report concomitant symptoms of angina. Treatment of such "silent" ischaemia aims mainly to reduce the risk of subsequent cardiac events. We have studied the effect of low-dose aspirin in patients with myocardial ischaemia defined at the predischarge test as silent (though patients might have had symptomatic ischaemia at other times) or symptomatic. 740 men with unstable CAD aged 70 years or less underwent symptom-limited exercise testing before hospital discharge; 144 showed ST depression without pain and 230 ST depression with simultaneous chest pain. Of the silent ischaemia group, 67 were randomly assigned placebo and 77 aspirin (75 mg daily); the corresponding numbers in the symptomatic group were 125 and 105. Angina symptoms were less common in the silent than in the symptomatic ischaemia group both before inclusion and during follow-up, and a greater proportion of the silent ischaemia group were included because of myocardial infarction. In both ischaemia groups aspirin treatment reduced the risk of subsequent myocardial infarction or death by 3 months' follow-up (silent 4% of aspirin-treated vs 21% of placebo-treated patients, p = 0.004; symptomatic 9% vs 18%, p = 0.05); at 12 months' follow-up a significant benefit of aspirin was still apparent in the silent ischaemia group (9% vs 28%, p = 0.005) but not in the symptomatic group (13% vs 22%, p = 0.109). Low-dose aspirin reduced the risk of subsequent myocardial infarction at least as well in silent as in symptomatic myocardial ischaemia. Since improvement of outlook is the main treatment objective in symptom-free patients, aspirin should be a mainstay of their treatment.
Authors:
I Nyman; H Larsson; L Wallentin
Related Documents :
18474534 - Early glycoprotein iib-iiia inhibitors in primary angioplasty (egypt) cooperation: an i...
1902404 - A randomized comparison of intravenous heparin with oral aspirin and dipyridamole 24 ho...
11835024 - Bivalirudin as a replacement for unfractionated heparin in unstable angina/non-st-eleva...
8279364 - Conjunctive antithrombotic therapy for thrombolysis in myocardial infarction.
9521334 - Abciximab therapy and unplanned coronary stent deployment: favorable effects on stent u...
11143764 - Triglycerides and coronary heart disease: implications of recent clinical trials.
Publication Detail:
Type:  Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Lancet     Volume:  340     ISSN:  0140-6736     ISO Abbreviation:  Lancet     Publication Date:  1992 Aug 
Date Detail:
Created Date:  1992-09-17     Completed Date:  1992-09-17     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  2985213R     Medline TA:  Lancet     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  497-501     Citation Subset:  AIM; IM    
Affiliation:
Department of Internal Medicine, District Hospital, Eksjö, Sweden.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Aspirin / therapeutic use*
Coronary Disease / prevention & control*
Double-Blind Method
Electrocardiography
Humans
Male
Middle Aged
Chemical
Reg. No./Substance:
50-78-2/Aspirin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The use of radioreceptor assays for the determination of benzodiazepines in biological samples: a re...
Next Document:  Randomised controlled trial of adjuvant chemotherapy by portal-vein perfusion after curative resecti...